SCHEMBL12371785

SCHEMBL12371785

O=c1[nH]c2cnc(NCC3CCCN3)nc2n1Cc1ccccc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCDIN3D Q7Z5W3 1/20 0.41
PDE9A O76083 2/20 0.40
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
PRKCQ Q04759 1/20 0.39
SYK P43405 2/20 0.38
KCNH2 Q12809 2/20 0.38
MAPK3 P27361 1/20 0.38
MAPK1 P28482 1/20 0.38
AURKB Q96GD4 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38
ALDH1A1 P00352 4/20 0.38
ADORA3 P0DMS8 1/20 0.38
MAPT P10636 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HTR3A P46098 1/20 0.38
TSHR P16473 2/20 0.38
HSD17B10 Q99714 2/20 0.38
THRB P10828 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12371781 0.89 HTR3A (0.40) PDE9AADORA2AADORA1ALDH1A1ADORA3
SCHEMBL12371697 0.86 PRKCQ (0.43) PDE9ACYP3A4CYP2C9PRKCQAURKB
SCHEMBL12371700 0.85 CYP2C9 (0.54) PDE9ACYP3A4CYP2C9PRKCQAURKB
SCHEMBL12371647 0.84 PRKCQ (0.48) PDE9ACYP3A4CYP2C9PRKCQAURKB
SCHEMBL12371664 0.84 PRKCQ (0.48) PDE9ACYP3A4CYP2C9PRKCQAURKB
SCHEMBL12371635 0.84 PRKCQ (0.48) PDE9ACYP3A4CYP2C9PRKCQAURKB
SCHEMBL12371706 0.81 ALDH1A1 (0.42) CYP3A4CYP2C9PRKCQAURKBADORA2A
SCHEMBL12371797 0.79 ALDH1A1 (0.43) CYP3A4CYP2C9PRKCQALDH1A1ADORA3
SCHEMBL12398979 0.78 POLB (0.41) SYKKCNH2ADORA3SMN1; SMN2JAK2
SCHEMBL12371758 0.78 CACNA1G (0.44) ADORA2AADORA1ALDH1A1ADORA3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989459-B2 Protein kinase C (PKC); rheumatoid arthritis, lupus, transplant rejection, asthma, inflammatory bowel disease, cancer and diabetes; for example, 2-(pyrrolidin-3-ylmethylamino)-9-(2-trifluoromethoxybenzyl)-7,8-dihydro-9H-purin-8-one PHARMACOPEIA, LLC (US) 2011-08-02 US disclosed
US-7989459-B2 Protein kinase C (PKC); rheumatoid arthritis, lupus, transplant rejection, asthma, inflammatory bowel disease, cancer and diabetes; for example, 2-(pyrrolidin-3-ylmethylamino)-9-(2-trifluoromethoxybenzyl)-7,8-dihydro-9H-purin-8-one PHARMACOPEIA, LLC (US) 2011-08-02 US disclosed
US-20080085909-A1 Purinones and 1H-imidazopyridinones as PKC-theta inhibitors PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2008-04-10 US disclosed
US-20080085909-A1 Purinones and 1H-imidazopyridinones as PKC-theta inhibitors PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2008-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085909-A1 Purinones and 1H-imidazopyridinones as PKC-theta inhibitors PRKCE, PRKCH, PRKCQ BCDIN3D 351/4885PDE9A 193/4885CYP3A4 2523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.